ALKS
Price
$24.65
Change
+$0.38 (+1.57%)
Updated
Apr 24, 6:59 PM EST
7 days until earnings call
SUPN
Price
$30.26
Change
+$0.31 (+1.04%)
Updated
Apr 24, 6:59 PM EST
13 days until earnings call
Ad is loading...

Analysis and predictions ALKS vs SUPN

Header iconALKS vs SUPN Comparison
Open Charts ALKS vs SUPNBanner chart's image
Alkermes
Price$24.65
Change+$0.38 (+1.57%)
Volume$1M
CapitalizationN/A
Supernus Pharmaceuticals
Price$30.26
Change+$0.31 (+1.04%)
Volume$99.44K
CapitalizationN/A
View a ticker or compare two or three
ALKS vs SUPN Comparison Chart

Loading...

ALKSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SUPNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ALKS vs. SUPN commentary
Apr 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a StrongBuy and SUPN is a Hold.

COMPARISON
Comparison
Apr 25, 2024
Stock price -- (ALKS: $24.26 vs. SUPN: $29.95)
Brand notoriety: ALKS and SUPN are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ALKS: 62% vs. SUPN: 47%
Market capitalization -- ALKS: $4.55B vs. SUPN: $1.84B
ALKS [@Pharmaceuticals: Other] is valued at $4.55B. SUPN’s [@Pharmaceuticals: Other] market capitalization is $1.84B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 1 FA rating(s) are green whileSUPN’s FA Score has 1 green FA rating(s).

  • ALKS’s FA Score: 1 green, 4 red.
  • SUPN’s FA Score: 1 green, 4 red.
According to our system of comparison, both ALKS and SUPN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 4 TA indicator(s) are bullish while SUPN’s TA Score has 5 bullish TA indicator(s).

  • ALKS’s TA Score: 4 bullish, 4 bearish.
  • SUPN’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, ALKS is a better buy in the short-term than SUPN.

Price Growth

ALKS (@Pharmaceuticals: Other) experienced а +2.06% price change this week, while SUPN (@Pharmaceuticals: Other) price change was +1.77% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.33%. For the same industry, the average monthly price growth was +27.90%, and the average quarterly price growth was +18903.16%.

Reported Earning Dates

ALKS is expected to report earnings on Jul 24, 2024.

SUPN is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (-1.33% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for ALKS with price predictions.
OPEN
A.I.dvisor published
a Summary for SUPN with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ALKS($4.55B) has a higher market cap than SUPN($1.84B). SUPN has higher P/E ratio than ALKS: SUPN (1677.00) vs ALKS (8.90). SUPN YTD gains are higher at: 3.490 vs. ALKS (-12.545). ALKS has higher annual earnings (EBITDA): 519M vs. SUPN (90M). ALKS has more cash in the bank: 773M vs. SUPN (255M). SUPN has less debt than ALKS: SUPN (41.5M) vs ALKS (372M). ALKS has higher revenues than SUPN: ALKS (1.66B) vs SUPN (608M).
ALKSSUPNALKS / SUPN
Capitalization4.55B1.84B248%
EBITDA519M90M577%
Gain YTD-12.5453.490-359%
P/E Ratio8.901677.001%
Revenue1.66B608M274%
Total Cash773M255M303%
Total Debt372M41.5M896%
FUNDAMENTALS RATINGS
ALKS vs SUPN: Fundamental Ratings
ALKS
SUPN
OUTLOOK RATING
1..100
6864
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3289
PRICE GROWTH RATING
1..100
6258
P/E GROWTH RATING
1..100
981
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALKS's Valuation (99) in the Biotechnology industry is in the same range as SUPN (99) in the Pharmaceuticals Other industry. This means that ALKS’s stock grew similarly to SUPN’s over the last 12 months.

ALKS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SUPN (100) in the Pharmaceuticals Other industry. This means that ALKS’s stock grew similarly to SUPN’s over the last 12 months.

ALKS's SMR Rating (32) in the Biotechnology industry is somewhat better than the same rating for SUPN (89) in the Pharmaceuticals Other industry. This means that ALKS’s stock grew somewhat faster than SUPN’s over the last 12 months.

SUPN's Price Growth Rating (58) in the Pharmaceuticals Other industry is in the same range as ALKS (62) in the Biotechnology industry. This means that SUPN’s stock grew similarly to ALKS’s over the last 12 months.

SUPN's P/E Growth Rating (1) in the Pharmaceuticals Other industry is significantly better than the same rating for ALKS (98) in the Biotechnology industry. This means that SUPN’s stock grew significantly faster than ALKS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSSUPN
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
70%
Declines
ODDS (%)
Bearish Trend 9 days ago
67%
Bearish Trend 7 days ago
68%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Ad is loading...
ALKSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SUPNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IPAY49.901.21
+2.49%
Amplify Mobile Payments ETF
IEV54.930.78
+1.44%
iShares Europe ETF
FLRG29.340.37
+1.28%
Fidelity U.S. Multifactor ETF
QSWN19.450.22
+1.13%
Amplify BlackSwan Tech & Treasury ETF
SDSI50.690.07
+0.14%
American Century® Short Dur Str Inc ETF

ALKS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with VTRS. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
+0.79%
VTRS - ALKS
34%
Loosely correlated
+0.98%
ACET - ALKS
30%
Poorly correlated
+5.00%
DCPH - ALKS
28%
Poorly correlated
+0.62%
ITCI - ALKS
26%
Poorly correlated
-0.71%
PAHC - ALKS
25%
Poorly correlated
+4.29%
More

SUPN and

Correlation & Price change

A.I.dvisor tells us that SUPN and SIGA have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SUPN and SIGA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SUPN
1D Price
Change %
SUPN100%
+0.81%
SIGA - SUPN
32%
Poorly correlated
+4.91%
AMPH - SUPN
31%
Poorly correlated
+1.84%
COLL - SUPN
31%
Poorly correlated
+3.45%
SNDL - SUPN
27%
Poorly correlated
+10.11%
ACET - SUPN
27%
Poorly correlated
+5.00%
More